Cabenuva is a complete HIV treatment regimen in a once-a-month or once-every-two-months injection. Combining two HIV medicines, cabotegravir and rilpivirine, it attacks the virus at different points in its life cycle. Cabenuva is made by ViiV Healthcare and was FDA-approved in January 2021 for monthly dosing and in February 2022 for bimonthly dosing. Cabenuva does not cure HIV, but when taken on schedule, it can suppress HIV to undetectable levels. Cabenuva is meant to replace a current HIV regimen that is already under control, not for those whose virus is not suppressed.
Cabenuva may be prescribed for the treatment of HIV in:
Cabotegravir, the INSTI in Cabenuva, blocks the enzyme that the virus uses to harm your CD4 cells, thus helping to protect your immune system. Without the enzyme, the virus can’t make copies of itself.
The NNRTI rilpivirine blocks reverse transcriptase, an enzyme HIV uses to make copies of its genetic material.
Both medicines are made to be extended-release suspensions that are injected into the muscles of the buttocks and release into the bloodstream over several weeks, meaning you’ll only need the injections at your regular appointments rather than every day.
Cabenuva is given to you by a healthcare provider as an intramuscular shot in each buttock during the same visit. It is not self-injected.
Before starting injections, some people first take two tablets, one containing cabotegravir and one containing rilpivirine, once a day for about a month to check how they tolerate the medicines. This oral lead-in is optional, and some people go straight from their current HIV regimen to injections.
Cabenuva dosing is as follows:
There is a flexible 7-day treatment window before or after your next scheduled injection appointment.
Sixteen percent of the participants in the FLAIR and ATLAS-2M phase 3 clinical trials for Cabenuva were Black or African descent. Over the course of 96 weeks, overall HIV suppression rates ranged from 83 to 94 percent across all racial groups, and treatment failure and serious side effects were low and similar between groups. Across all races, treatment satisfaction scores were up. ATLAS-2M also showed that the every-two-month dosing worked as well as the monthly dose.
The ongoing BEYOND study tracking people who switched to Cabenuva revealed that 98 percent have remained undetectable for 24 months and only 2 percent stopped due to injection site reactions.
Possible side effects include:
Seek medical treatment right away for:
The importance of staying on schedule
Cabenuva can stay in your body for up to a year or longer after your last injection, but that is not an excuse to miss or skip doses. If you need to stop Cabenuva for any reason, your doctor will place you on a different suppressive HIV regimen soon after your last dose (within about a month if you were on monthly dosing, or two months if you were on the every-two-months schedule) so the virus doesn’t get a chance to resist the medication.
Cabenuva should never be taken with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin, rifampin, rifabutin, or rifapentine; more than a single dose of dexamethasone; or the herbal supplement St. John’s wort. Always tell your doctor about every medication, supplement, herbal product, and over-the-counter drug you take so they can check for these interactions before you start Cabenuva.
Tell your healthcare provider if you have:
Black people tend to be hit the hardest with HIV, making up 39 percent of new HIV diagnoses in 2024, despite being only 12 percent of the U.S. population. Black people with HIV are also among the least likely of any race to receive medical care within a month of diagnosis. Gaps in treatment can stem from insurance coverage, transportation, housing instability, provider bias, and medical mistrust. Needing a monthly or bimonthly clinic visit can add another hurdle for Black patients compared to a daily take-anywhere pill.
It is also worth noting that the weight gain observed in Black women on certain HIV medications can be a potential drawback, since Black people already face hypertension, diabetes, and heart disease. Don’t be afraid to ask your provider about your options if this is a concern.
ViiV Healthcare offers the ViiVConnect Copay Program that brings your out-of-pocket cost for Cabenuva as low as $0 a month if you have private or commercial insurance. This copay program is unavailable to people enrolled in Medicare, Medicaid, or other government drug programs. If you are uninsured or underinsured, ViiVConnect can help you look into more assistance options. Call 1-844-588-3288 or visit viivconnect.com for more information.
Outside of ViiV Healthcare’s program, every state has an AIDS Drug Assistance Program (ADAP) that helps cover HIV medication costs for those who are uninsured or underinsured and meet certain income limits.
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking any drug or commencing or discontinuing any course of treatment.
Cabenuva is not recommended for those who are pregnant with HIV yet because there is not enough safety data available, not because Cabenuva is unsafe. Always tell your doctor if you become pregnant on Cabenuva. They may encourage you to switch regimens.
There is no evidence that Cabenuva affects fertility in male or female patients with HIV.
Cabenuva has not been well-studied in breastfeeding and the medication can remain in the body, including breastmilk, for several months after your last injection. Always ask your doctor before you consider breastfeeding on Cabenuva.
You may gain weight on Cabenuva, but studies have shown minimal weight gain on Cabenuva compared to other HIV medications. In the largest North American cohort analysis, Black women gained the most weight while taking INSTI-based HIV medications in general. If you are concerned about weight gain while on Cabenuva, ask your doctor about all of your options.
If your viral load is undetectable while on Cabenuva, you cannot transmit HIV through sex. Undetectable = Untransmittable, or U=U, applies. U=U does not apply to sharing needles or breastfeeding.